Safety and Comparability of Controlled Human Plasmodium falciparum Infection by Mosquito Bite in Malaria-Naïve Subjects at a New Facility for Sporozoite Challenge
Controlled human malaria infection (CHMI) studies which recapitulate mosquito-borne infection are a critical tool to identify protective vaccine and drug candidates for advancement to field trials. In partnership with the Walter Reed Army Institute of Research, the CHMI model was established at the...
Saved in:
| Published in | PloS one Vol. 9; no. 11; p. e109654 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
18.11.2014
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1932-6203 1932-6203 |
| DOI | 10.1371/journal.pone.0109654 |
Cover
| Abstract | Controlled human malaria infection (CHMI) studies which recapitulate mosquito-borne infection are a critical tool to identify protective vaccine and drug candidates for advancement to field trials. In partnership with the Walter Reed Army Institute of Research, the CHMI model was established at the Seattle Biomedical Research Institute's Malaria Clinical Trials Center (MCTC). Activities and reagents at both centers were aligned to ensure comparability and continued safety of the model. To demonstrate successful implementation, CHMI was performed in six healthy malaria-naïve volunteers.
All volunteers received NF54 strain Plasmodium falciparum by the bite of five infected Anopheles stephensi mosquitoes under controlled conditions and were monitored for signs and symptoms of malaria and for parasitemia by peripheral blood smear. Subjects were treated upon diagnosis with chloroquine by directly observed therapy. Immunological (T cell and antibody) and molecular diagnostic (real-time quantitative reverse transcriptase polymerase chain reaction [qRT-PCR]) assessments were also performed.
All six volunteers developed patent parasitemia and clinical malaria. No serious adverse events occurred during the study period or for six months post-infection. The mean prepatent period was 11.2 days (range 9-14 days), and geometric mean parasitemia upon diagnosis was 10.8 parasites/µL (range 2-69) by microscopy. qRT-PCR detected parasites an average of 3.7 days (range 2-4 days) earlier than blood smears. All volunteers developed antibodies to the blood-stage antigen merozoite surface protein 1 (MSP-1), which persisted up to six months. Humoral and cellular responses to pre-erythrocytic antigens circumsporozoite protein (CSP) and liver-stage antigen 1 (LSA-1) were limited.
The CHMI model was safe, well tolerated and characterized by consistent prepatent periods, pre-symptomatic diagnosis in 3/6 subjects and adverse event profiles as reported at established centers. The MCTC can now evaluate candidates in the increasingly diverse vaccine and drug pipeline using the CHMI model.
ClinicalTrials.gov NCT01058226. |
|---|---|
| AbstractList | Background
Controlled human malaria infection (CHMI) studies which recapitulate mosquito-borne infection are a critical tool to identify protective vaccine and drug candidates for advancement to field trials. In partnership with the Walter Reed Army Institute of Research, the CHMI model was established at the Seattle Biomedical Research Institute's Malaria Clinical Trials Center (MCTC). Activities and reagents at both centers were aligned to ensure comparability and continued safety of the model. To demonstrate successful implementation, CHMI was performed in six healthy malaria-naïve volunteers.
Methods
All volunteers received NF54 strain Plasmodium falciparum by the bite of five infected Anopheles stephensi mosquitoes under controlled conditions and were monitored for signs and symptoms of malaria and for parasitemia by peripheral blood smear. Subjects were treated upon diagnosis with chloroquine by directly observed therapy. Immunological (T cell and antibody) and molecular diagnostic (real-time quantitative reverse transcriptase polymerase chain reaction [qRT-PCR]) assessments were also performed.
Results
All six volunteers developed patent parasitemia and clinical malaria. No serious adverse events occurred during the study period or for six months post-infection. The mean prepatent period was 11.2 days (range 9–14 days), and geometric mean parasitemia upon diagnosis was 10.8 parasites/µL (range 2–69) by microscopy. qRT-PCR detected parasites an average of 3.7 days (range 2–4 days) earlier than blood smears. All volunteers developed antibodies to the blood-stage antigen merozoite surface protein 1 (MSP-1), which persisted up to six months. Humoral and cellular responses to pre-erythrocytic antigens circumsporozoite protein (CSP) and liver-stage antigen 1 (LSA-1) were limited.
Conclusion
The CHMI model was safe, well tolerated and characterized by consistent prepatent periods, pre-symptomatic diagnosis in 3/6 subjects and adverse event profiles as reported at established centers. The MCTC can now evaluate candidates in the increasingly diverse vaccine and drug pipeline using the CHMI model.
Trial Registration
ClinicalTrials.gov NCT01058226 Controlled human malaria infection (CHMI) studies which recapitulate mosquito-borne infection are a critical tool to identify protective vaccine and drug candidates for advancement to field trials. In partnership with the Walter Reed Army Institute of Research, the CHMI model was established at the Seattle Biomedical Research Institute's Malaria Clinical Trials Center (MCTC). Activities and reagents at both centers were aligned to ensure comparability and continued safety of the model. To demonstrate successful implementation, CHMI was performed in six healthy malaria-naïve volunteers.BACKGROUNDControlled human malaria infection (CHMI) studies which recapitulate mosquito-borne infection are a critical tool to identify protective vaccine and drug candidates for advancement to field trials. In partnership with the Walter Reed Army Institute of Research, the CHMI model was established at the Seattle Biomedical Research Institute's Malaria Clinical Trials Center (MCTC). Activities and reagents at both centers were aligned to ensure comparability and continued safety of the model. To demonstrate successful implementation, CHMI was performed in six healthy malaria-naïve volunteers.All volunteers received NF54 strain Plasmodium falciparum by the bite of five infected Anopheles stephensi mosquitoes under controlled conditions and were monitored for signs and symptoms of malaria and for parasitemia by peripheral blood smear. Subjects were treated upon diagnosis with chloroquine by directly observed therapy. Immunological (T cell and antibody) and molecular diagnostic (real-time quantitative reverse transcriptase polymerase chain reaction [qRT-PCR]) assessments were also performed.METHODSAll volunteers received NF54 strain Plasmodium falciparum by the bite of five infected Anopheles stephensi mosquitoes under controlled conditions and were monitored for signs and symptoms of malaria and for parasitemia by peripheral blood smear. Subjects were treated upon diagnosis with chloroquine by directly observed therapy. Immunological (T cell and antibody) and molecular diagnostic (real-time quantitative reverse transcriptase polymerase chain reaction [qRT-PCR]) assessments were also performed.All six volunteers developed patent parasitemia and clinical malaria. No serious adverse events occurred during the study period or for six months post-infection. The mean prepatent period was 11.2 days (range 9-14 days), and geometric mean parasitemia upon diagnosis was 10.8 parasites/µL (range 2-69) by microscopy. qRT-PCR detected parasites an average of 3.7 days (range 2-4 days) earlier than blood smears. All volunteers developed antibodies to the blood-stage antigen merozoite surface protein 1 (MSP-1), which persisted up to six months. Humoral and cellular responses to pre-erythrocytic antigens circumsporozoite protein (CSP) and liver-stage antigen 1 (LSA-1) were limited.RESULTSAll six volunteers developed patent parasitemia and clinical malaria. No serious adverse events occurred during the study period or for six months post-infection. The mean prepatent period was 11.2 days (range 9-14 days), and geometric mean parasitemia upon diagnosis was 10.8 parasites/µL (range 2-69) by microscopy. qRT-PCR detected parasites an average of 3.7 days (range 2-4 days) earlier than blood smears. All volunteers developed antibodies to the blood-stage antigen merozoite surface protein 1 (MSP-1), which persisted up to six months. Humoral and cellular responses to pre-erythrocytic antigens circumsporozoite protein (CSP) and liver-stage antigen 1 (LSA-1) were limited.The CHMI model was safe, well tolerated and characterized by consistent prepatent periods, pre-symptomatic diagnosis in 3/6 subjects and adverse event profiles as reported at established centers. The MCTC can now evaluate candidates in the increasingly diverse vaccine and drug pipeline using the CHMI model.CONCLUSIONThe CHMI model was safe, well tolerated and characterized by consistent prepatent periods, pre-symptomatic diagnosis in 3/6 subjects and adverse event profiles as reported at established centers. The MCTC can now evaluate candidates in the increasingly diverse vaccine and drug pipeline using the CHMI model.ClinicalTrials.gov NCT01058226.TRIAL REGISTRATIONClinicalTrials.gov NCT01058226. Controlled human malaria infection (CHMI) studies which recapitulate mosquito-borne infection are a critical tool to identify protective vaccine and drug candidates for advancement to field trials. In partnership with the Walter Reed Army Institute of Research, the CHMI model was established at the Seattle Biomedical Research Institute's Malaria Clinical Trials Center (MCTC). Activities and reagents at both centers were aligned to ensure comparability and continued safety of the model. To demonstrate successful implementation, CHMI was performed in six healthy malaria-naïve volunteers. All volunteers received NF54 strain Plasmodium falciparum by the bite of five infected Anopheles stephensi mosquitoes under controlled conditions and were monitored for signs and symptoms of malaria and for parasitemia by peripheral blood smear. Subjects were treated upon diagnosis with chloroquine by directly observed therapy. Immunological (T cell and antibody) and molecular diagnostic (real-time quantitative reverse transcriptase polymerase chain reaction [qRT-PCR]) assessments were also performed. All six volunteers developed patent parasitemia and clinical malaria. No serious adverse events occurred during the study period or for six months post-infection. The mean prepatent period was 11.2 days (range 9-14 days), and geometric mean parasitemia upon diagnosis was 10.8 parasites/µL (range 2-69) by microscopy. qRT-PCR detected parasites an average of 3.7 days (range 2-4 days) earlier than blood smears. All volunteers developed antibodies to the blood-stage antigen merozoite surface protein 1 (MSP-1), which persisted up to six months. Humoral and cellular responses to pre-erythrocytic antigens circumsporozoite protein (CSP) and liver-stage antigen 1 (LSA-1) were limited. The CHMI model was safe, well tolerated and characterized by consistent prepatent periods, pre-symptomatic diagnosis in 3/6 subjects and adverse event profiles as reported at established centers. The MCTC can now evaluate candidates in the increasingly diverse vaccine and drug pipeline using the CHMI model. ClinicalTrials.gov NCT01058226. Controlled human malaria infection (CHMI) studies which recapitulate mosquito-borne infection are a critical tool to identify protective vaccine and drug candidates for advancement to field trials. In partnership with the Walter Reed Army Institute of Research, the CHMI model was established at the Seattle Biomedical Research Institute's Malaria Clinical Trials Center (MCTC). Activities and reagents at both centers were aligned to ensure comparability and continued safety of the model. To demonstrate successful implementation, CHMI was performed in six healthy malaria-naïve volunteers.All volunteers received NF54 strain Plasmodium falciparum by the bite of five infected Anopheles stephensi mosquitoes under controlled conditions and were monitored for signs and symptoms of malaria and for parasitemia by peripheral blood smear. Subjects were treated upon diagnosis with chloroquine by directly observed therapy. Immunological (T cell and antibody) and molecular diagnostic (real-time quantitative reverse transcriptase polymerase chain reaction [qRT-PCR]) assessments were also performed.All six volunteers developed patent parasitemia and clinical malaria. No serious adverse events occurred during the study period or for six months post-infection. The mean prepatent period was 11.2 days (range 9-14 days), and geometric mean parasitemia upon diagnosis was 10.8 parasites/µL (range 2-69) by microscopy. qRT-PCR detected parasites an average of 3.7 days (range 2-4 days) earlier than blood smears. All volunteers developed antibodies to the blood-stage antigen merozoite surface protein 1 (MSP-1), which persisted up to six months. Humoral and cellular responses to pre-erythrocytic antigens circumsporozoite protein (CSP) and liver-stage antigen 1 (LSA-1) were limited.The CHMI model was safe, well tolerated and characterized by consistent prepatent periods, pre-symptomatic diagnosis in 3/6 subjects and adverse event profiles as reported at established centers. The MCTC can now evaluate candidates in the increasingly diverse vaccine and drug pipeline using the CHMI model.ClinicalTrials.gov NCT01058226. Background Controlled human malaria infection (CHMI) studies which recapitulate mosquito-borne infection are a critical tool to identify protective vaccine and drug candidates for advancement to field trials. In partnership with the Walter Reed Army Institute of Research, the CHMI model was established at the Seattle Biomedical Research Institute's Malaria Clinical Trials Center (MCTC). Activities and reagents at both centers were aligned to ensure comparability and continued safety of the model. To demonstrate successful implementation, CHMI was performed in six healthy malaria-naïve volunteers. Methods All volunteers received NF54 strain Plasmodium falciparum by the bite of five infected Anopheles stephensi mosquitoes under controlled conditions and were monitored for signs and symptoms of malaria and for parasitemia by peripheral blood smear. Subjects were treated upon diagnosis with chloroquine by directly observed therapy. Immunological (T cell and antibody) and molecular diagnostic (real-time quantitative reverse transcriptase polymerase chain reaction [qRT-PCR]) assessments were also performed. Results All six volunteers developed patent parasitemia and clinical malaria. No serious adverse events occurred during the study period or for six months post-infection. The mean prepatent period was 11.2 days (range 9–14 days), and geometric mean parasitemia upon diagnosis was 10.8 parasites/µL (range 2–69) by microscopy. qRT-PCR detected parasites an average of 3.7 days (range 2–4 days) earlier than blood smears. All volunteers developed antibodies to the blood-stage antigen merozoite surface protein 1 (MSP-1), which persisted up to six months. Humoral and cellular responses to pre-erythrocytic antigens circumsporozoite protein (CSP) and liver-stage antigen 1 (LSA-1) were limited. Conclusion The CHMI model was safe, well tolerated and characterized by consistent prepatent periods, pre-symptomatic diagnosis in 3/6 subjects and adverse event profiles as reported at established centers. The MCTC can now evaluate candidates in the increasingly diverse vaccine and drug pipeline using the CHMI model. Trial Registration ClinicalTrials.gov NCT01058226 |
| Author | Duffy, Patrick E. Finney, Olivia C. Ockenhouse, Chris F. Kappe, Stefan H. Salas, Carola J. Whisler, John Talley, Angela K. Kublin, James Van Voorhis, Wesley C. Heppner, D. Gray Healy, Sara A. Wang, Ruobing Lundebjerg, Susan Gilbert, Peter Murphy, Sean C. |
| AuthorAffiliation | Mahidol-Oxford Tropical Medicine Research Unit, Thailand 5 United States Naval Medical Research Unit Number 6, Lima, Peru 3 Department of Laboratory Medicine, University of Washington Medical Center, Seattle, Washington, United States of America 7 United States Military Malaria Vaccine Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America 1 Malaria Clinical Trials Center, Seattle Biomedical Research Institute, Seattle, Washington, United States of America 2 Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America 6 Department of Medicine, University of Washington Medical Center, Seattle, Washington, United States of America 4 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America |
| AuthorAffiliation_xml | – name: 4 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America – name: 7 United States Military Malaria Vaccine Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America – name: 6 Department of Medicine, University of Washington Medical Center, Seattle, Washington, United States of America – name: Mahidol-Oxford Tropical Medicine Research Unit, Thailand – name: 5 United States Naval Medical Research Unit Number 6, Lima, Peru – name: 2 Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America – name: 1 Malaria Clinical Trials Center, Seattle Biomedical Research Institute, Seattle, Washington, United States of America – name: 3 Department of Laboratory Medicine, University of Washington Medical Center, Seattle, Washington, United States of America |
| Author_xml | – sequence: 1 givenname: Angela K. surname: Talley fullname: Talley, Angela K. – sequence: 2 givenname: Sara A. surname: Healy fullname: Healy, Sara A. – sequence: 3 givenname: Olivia C. surname: Finney fullname: Finney, Olivia C. – sequence: 4 givenname: Sean C. surname: Murphy fullname: Murphy, Sean C. – sequence: 5 givenname: James surname: Kublin fullname: Kublin, James – sequence: 6 givenname: Carola J. surname: Salas fullname: Salas, Carola J. – sequence: 7 givenname: Susan surname: Lundebjerg fullname: Lundebjerg, Susan – sequence: 8 givenname: Peter surname: Gilbert fullname: Gilbert, Peter – sequence: 9 givenname: Wesley C. surname: Van Voorhis fullname: Van Voorhis, Wesley C. – sequence: 10 givenname: John surname: Whisler fullname: Whisler, John – sequence: 11 givenname: Ruobing surname: Wang fullname: Wang, Ruobing – sequence: 12 givenname: Chris F. surname: Ockenhouse fullname: Ockenhouse, Chris F. – sequence: 13 givenname: D. Gray surname: Heppner fullname: Heppner, D. Gray – sequence: 14 givenname: Stefan H. surname: Kappe fullname: Kappe, Stefan H. – sequence: 15 givenname: Patrick E. surname: Duffy fullname: Duffy, Patrick E. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25405724$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktuFDEQhlsoiDzgBggssWEzg1_tbrOIBCNCIiUBaWBtVbvtxCN3e2J3Bw3X4QAcgovhyUyiJEKsXCp_9ddD_36x04feFMVLgqeEVeTdIoyxBz9d5vQUEyxFyZ8Ue0QyOhEUs5178W6xn9IC45LVQjwrdmnJcVlRvlf8moM1wwpB36JZ6JYQoXHe5UywOdEPMXhvWnQ8dtCjrx5SF1o3dsiC1y7jOTzprdGDCz1qVugspKvRDQF9dINBrkdn4CE6mJzDn9_XBs3HZpHphGBAgM7ND3QEetPRhojmyxDDz7CunV1Cbt1fmOfF09wtmRfb96D4fvTp2-x4cvrl88nsw-lEl1QMk5IQCsIwW4G0uMKypRyallJjgZlGUkmwqAGIqGtZM9LISjNNRA4a3rTADorXG92lD0lt75sUEbSsa45rnomTDdEGWKhldB3ElQrg1E0ixAsFcXDaGyVbo3FLLcOy5gBMSs25biwmVdtYQ7PW4bbb2HSm1SbfGvwD0Yc_vbtUF-FaccoE5iILvN0KxHA1mjSoziVtvIfehPFm7gpXJWNr9M0j9N_bvbo_0d0ot27JAN8AOoaUorF3CMFqbcpbWbU2pdqaMpe9f1Sm3QBrw-S9nP9_8V-Woe8Q |
| CitedBy_id | crossref_primary_10_1186_s12936_016_1675_x crossref_primary_10_1038_scibx_2014_1398 crossref_primary_10_1186_s12936_016_1434_z crossref_primary_10_1186_s12936_024_04959_2 crossref_primary_10_1093_cid_ciz1010 crossref_primary_10_1186_s12936_021_03717_y crossref_primary_10_1128_cmr_00008_21 crossref_primary_10_1093_ofid_ofad202 crossref_primary_10_1016_j_coi_2015_06_008 crossref_primary_10_1038_s41467_021_21269_2 crossref_primary_10_1016_j_ttbdis_2015_12_012 crossref_primary_10_1186_s12879_021_06953_4 crossref_primary_10_1093_infdis_jix613 crossref_primary_10_1017_S0031182015000761 crossref_primary_10_1126_scitranslmed_abn9709 crossref_primary_10_1126_scitranslmed_aad9099 crossref_primary_10_1371_journal_pmed_1002451 crossref_primary_10_4269_ajtmh_19_0846 |
| Cites_doi | 10.4269/ajtmh.2011.09-0498 10.1093/infdis/jit156 10.1016/S0035-9203(31)90068-0 10.1016/j.vaccine.2012.04.088 10.1097/QAI.0b013e3180377b5b 10.1016/j.vaccine.2007.10.064 10.1093/infdis/jiu063 10.4269/ajtmh.2012.10-0658 10.1371/journal.pone.0097398 10.1086/513990 10.1128/JCM.02549-12 10.4269/ajtmh.2009.09-0194 10.4269/ajtmh.2004.71.239 10.1086/427243 10.1016/S0140-6736(08)60418-3 10.1371/journal.pone.0038434 10.1016/S0140-6736(08)61592-5 10.1086/518510 10.1002/eji.1830220311 10.4269/ajtmh.1986.35.66 10.7326/0003-4819-127-3-199708010-00010 10.1002/eji.200939434 10.1056/NEJMoa0805832 10.1371/journal.pone.0013490 |
| ContentType | Journal Article |
| Copyright | 2014. This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2014 |
| Copyright_xml | – notice: 2014. This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2014 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0109654 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Materials Science & Engineering ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Local Electronic Collection Information Biological Science Database ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ (Directory of Open Access Journals) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Agricultural Science Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Controlled Human P. falciparum Malaria Infection at a New Facility |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1625884084 oai_doaj_org_article_9dec0d2f30984aa399c44cbf017dbfe2 PMC4236046 3500204561 25405724 10_1371_journal_pone_0109654 |
| Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, N.I.H., Intramural Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: NICHD NIH HHS grantid: T32 HD007233 – fundername: Intramural NIH HHS |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PYCSY RNS RPM SV3 TR2 UKHRP WOQ WOW ~02 ~KM CGR CUY CVF ECM EIF IPNFZ NPM PJZUB PPXIY PQGLB PV9 RIG RZL 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 ESTFP PUEGO 5PM - 02 AAPBV ABPTK ADACO BBAFP BBORY KM |
| ID | FETCH-LOGICAL-c526t-5112a6e3f7a9f0709d24abd22efa3eb9291068aa16889831b97c3c161b9b4bda3 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Fri Nov 26 17:14:38 EST 2021 Wed Aug 27 01:31:19 EDT 2025 Thu Aug 21 13:55:38 EDT 2025 Mon Sep 08 15:35:05 EDT 2025 Fri Jul 25 10:37:57 EDT 2025 Mon Jul 21 05:38:01 EDT 2025 Tue Jul 01 01:54:26 EDT 2025 Thu Apr 24 22:58:12 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. Creative Commons CC0 public domain |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c526t-5112a6e3f7a9f0709d24abd22efa3eb9291068aa16889831b97c3c161b9b4bda3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 Conceived and designed the experiments: AKT SHK PED. Performed the experiments: AKT SAH OCF SCM CJS RW. Analyzed the data: AKT OCF SCM JK PG WCVV RW PED. Contributed reagents/materials/analysis tools: SL JW CFO DGH. Wrote the paper: AKT SCM DGH PED. Competing Interests: The authors have declared that no competing interests exist. |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0109654 |
| PMID | 25405724 |
| PQID | 1625884084 |
| PQPubID | 1436336 |
| ParticipantIDs | plos_journals_1625884084 doaj_primary_oai_doaj_org_article_9dec0d2f30984aa399c44cbf017dbfe2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4236046 proquest_miscellaneous_1627075336 proquest_journals_1625884084 pubmed_primary_25405724 crossref_primary_10_1371_journal_pone_0109654 crossref_citationtrail_10_1371_journal_pone_0109654 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-11-18 |
| PublicationDateYYYYMMDD | 2014-11-18 |
| PublicationDate_xml | – month: 11 year: 2014 text: 2014-11-18 day: 18 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2014 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | SP James (ref22) 1931; 24 SC Murphy (ref25) 2012; 50 SL Hoffman (ref7) 1997; 127 WD Nicol (ref21) 1927; 6 LW Church (ref1) 1997; 175 M Spring (ref8) 2014; 209 JE Epstein (ref6) 2007; 196 S Herrera (ref9) 2011; 84 AD Douglas (ref11) 2013; 208 P Bejon (ref12) 2005; 191 M Roestenberg (ref13) 2012; 7 Y Zevering (ref26) 1992; 22 SM Todryk (ref27) 2009; 39 S Herrera (ref10) 2009; 81 TA Gaziano (ref15) 2008; 371 JD Chulay (ref5) 1986; 35 ref20 KE Lyke (ref3) 2010; 5 SC Murphy (ref16) 2012; 86 DF Verhage (ref4) 2005; 63 WR Ballou (ref14) 2004; 71 MJ McElrath (ref18) 2008; 372 K Miura (ref17) 2008; 26 SC Murphy (ref24) 2014; 9 S Dubey (ref19) 2007; 45 MB Laurens (ref23) 2012; 30 M Roestenberg (ref2) 2009; 361 19012957 - Lancet. 2008 Nov 29;372(9653):1894-905 18054414 - Vaccine. 2008 Jan 10;26(2):193-200 17310936 - J Acquir Immune Defic Syndr. 2007 May 1;45(1):20-7 23052309 - J Clin Microbiol. 2012 Dec;50(12):4128-30 21042404 - PLoS One. 2010;5(10):e13490 1547814 - Eur J Immunol. 1992 Mar;22(3):689-96 15768480 - Neth J Med. 2005 Feb;63(2):52-8 17538895 - J Infect Dis. 2007 Jul 1;196(1):145-54 19641203 - N Engl J Med. 2009 Jul 30;361(5):468-77 19861603 - Am J Trop Med Hyg. 2009 Nov;81(5):740-6 3511753 - Am J Trop Med Hyg. 1986 Jan;35(1):66-8 9086149 - J Infect Dis. 1997 Apr;175(4):915-20 22659449 - Vaccine. 2012 Aug 3;30(36):5302-4 15331843 - Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):239-47 24872394 - J Infect Dis. 2014 Jun 15;209 Suppl 2:S40-5 24838112 - PLoS One. 2014;9(5):e97398 15655787 - J Infect Dis. 2005 Feb 15;191(4):619-26 18342687 - Lancet. 2008 Mar 15;371(9616):923-31 21292872 - Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):4-11 23570846 - J Infect Dis. 2013 Jul 15;208(2):340-5 22403305 - Am J Trop Med Hyg. 2012 Mar;86(3):383-94 9245231 - Ann Intern Med. 1997 Aug 1;127(3):233-5 19658096 - Eur J Immunol. 2009 Nov;39(11):3042-51 22701640 - PLoS One. 2012;7(6):e38434 |
| References_xml | – volume: 84 start-page: 4 year: 2011 ident: ref9 article-title: Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.2011.09-0498 – volume: 208 start-page: 340 year: 2013 ident: ref11 article-title: Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection publication-title: J Infect Dis doi: 10.1093/infdis/jit156 – volume: 24 start-page: 477 year: 1931 ident: ref22 article-title: Some general results of a study of induced malaria in England publication-title: Trans R Soc Trop Med Hyg doi: 10.1016/S0035-9203(31)90068-0 – ident: ref20 – volume: 30 start-page: 5302 year: 2012 ident: ref23 article-title: A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2012.04.088 – volume: 45 start-page: 20 year: 2007 ident: ref19 article-title: Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3180377b5b – volume: 63 start-page: 52 year: 2005 ident: ref4 article-title: Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes publication-title: Neth J Med – volume: 26 start-page: 193 year: 2008 ident: ref17 article-title: Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2007.10.064 – volume: 209 start-page: S40 year: 2014 ident: ref8 article-title: Controlled human malaria infection publication-title: J Infect Dis doi: 10.1093/infdis/jiu063 – volume: 6 start-page: 1 year: 1927 ident: ref21 article-title: The care and management of induced malaria publication-title: J Ment Sci – volume: 86 start-page: 383 year: 2012 ident: ref16 article-title: Real-time quantitative reverse transcription PCR for monitoring of blood-stage Plasmodium falciparum infections in malaria human challenge trials publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.2012.10-0658 – volume: 9 start-page: e97398 year: 2014 ident: ref24 article-title: External quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillance publication-title: PLoS One doi: 10.1371/journal.pone.0097398 – volume: 175 start-page: 915 year: 1997 ident: ref1 article-title: Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge publication-title: J Infect Dis doi: 10.1086/513990 – volume: 50 start-page: 4128 year: 2012 ident: ref25 article-title: Laser cutting eliminates nucleic acid cross-contamination in dried-blood-spot processing publication-title: J Clin Microbiol doi: 10.1128/JCM.02549-12 – volume: 81 start-page: 740 year: 2009 ident: ref10 article-title: Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.2009.09-0194 – volume: 71 start-page: 239 year: 2004 ident: ref14 article-title: Update on the clinical development of candidate malaria vaccines publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.2004.71.239 – volume: 191 start-page: 619 year: 2005 ident: ref12 article-title: Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites publication-title: J Infect Dis doi: 10.1086/427243 – volume: 371 start-page: 923 year: 2008 ident: ref15 article-title: Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort publication-title: Lancet doi: 10.1016/S0140-6736(08)60418-3 – volume: 7 start-page: e38434 year: 2012 ident: ref13 article-title: Comparison of clinical and parasitological data from controlled human malaria infection trials publication-title: PLoS One doi: 10.1371/journal.pone.0038434 – volume: 372 start-page: 1894 year: 2008 ident: ref18 article-title: HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis publication-title: Lancet doi: 10.1016/S0140-6736(08)61592-5 – volume: 196 start-page: 145 year: 2007 ident: ref6 article-title: Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update publication-title: J Infect Dis doi: 10.1086/518510 – volume: 22 start-page: 689 year: 1992 ident: ref26 article-title: High frequency of malaria-specific T cells in non-exposed humans publication-title: Eur J Immunol doi: 10.1002/eji.1830220311 – volume: 35 start-page: 66 year: 1986 ident: ref5 article-title: Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.1986.35.66 – volume: 127 start-page: 233 year: 1997 ident: ref7 article-title: Experimental challenge of volunteers with malaria publication-title: Ann Intern Med doi: 10.7326/0003-4819-127-3-199708010-00010 – volume: 39 start-page: 3042 year: 2009 ident: ref27 article-title: Multiple functions of human T cells generated by experimental malaria challenge publication-title: Eur J Immunol doi: 10.1002/eji.200939434 – volume: 361 start-page: 468 year: 2009 ident: ref2 article-title: Protection against a malaria challenge by sporozoite inoculation publication-title: N Engl J Med doi: 10.1056/NEJMoa0805832 – volume: 5 start-page: e13490 year: 2010 ident: ref3 article-title: Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial publication-title: PLoS One doi: 10.1371/journal.pone.0013490 – reference: 22701640 - PLoS One. 2012;7(6):e38434 – reference: 23570846 - J Infect Dis. 2013 Jul 15;208(2):340-5 – reference: 24872394 - J Infect Dis. 2014 Jun 15;209 Suppl 2:S40-5 – reference: 9086149 - J Infect Dis. 1997 Apr;175(4):915-20 – reference: 21292872 - Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):4-11 – reference: 9245231 - Ann Intern Med. 1997 Aug 1;127(3):233-5 – reference: 19012957 - Lancet. 2008 Nov 29;372(9653):1894-905 – reference: 19641203 - N Engl J Med. 2009 Jul 30;361(5):468-77 – reference: 21042404 - PLoS One. 2010;5(10):e13490 – reference: 15655787 - J Infect Dis. 2005 Feb 15;191(4):619-26 – reference: 22403305 - Am J Trop Med Hyg. 2012 Mar;86(3):383-94 – reference: 24838112 - PLoS One. 2014;9(5):e97398 – reference: 1547814 - Eur J Immunol. 1992 Mar;22(3):689-96 – reference: 19658096 - Eur J Immunol. 2009 Nov;39(11):3042-51 – reference: 17310936 - J Acquir Immune Defic Syndr. 2007 May 1;45(1):20-7 – reference: 23052309 - J Clin Microbiol. 2012 Dec;50(12):4128-30 – reference: 19861603 - Am J Trop Med Hyg. 2009 Nov;81(5):740-6 – reference: 15331843 - Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):239-47 – reference: 18054414 - Vaccine. 2008 Jan 10;26(2):193-200 – reference: 3511753 - Am J Trop Med Hyg. 1986 Jan;35(1):66-8 – reference: 17538895 - J Infect Dis. 2007 Jul 1;196(1):145-54 – reference: 22659449 - Vaccine. 2012 Aug 3;30(36):5302-4 – reference: 15768480 - Neth J Med. 2005 Feb;63(2):52-8 – reference: 18342687 - Lancet. 2008 Mar 15;371(9616):923-31 |
| SSID | ssj0053866 |
| Score | 2.2571301 |
| Snippet | Controlled human malaria infection (CHMI) studies which recapitulate mosquito-borne infection are a critical tool to identify protective vaccine and drug... Background Controlled human malaria infection (CHMI) studies which recapitulate mosquito-borne infection are a critical tool to identify protective vaccine and... Background Controlled human malaria infection (CHMI) studies which recapitulate mosquito-borne infection are a critical tool to identify protective vaccine and... |
| SourceID | plos doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e109654 |
| SubjectTerms | Adult Animals Anopheles - parasitology Anopheles - physiology Antibodies Antigens Aquatic insects Biology and Life Sciences Biomedical research Bites and Stings - parasitology Blood Chloroquine Circumsporozoite protein Clinical trials Controlled conditions Culicidae Diagnosis Diagnostic systems Drug development Drug dosages Enrollments Female Human Experimentation Humans Immunology Infections Infectious diseases Insect bites Laboratories Liver Lymphocytes T Malaria Malaria, Falciparum - complications Malaria, Falciparum - diagnosis Malaria, Falciparum - etiology Malaria, Falciparum - immunology Male Medical research Medicine and Health Sciences Merozoite surface protein 1 Microscopy Mosquitoes Parasitemia Parasites Peripheral blood Plasmodium falciparum Plasmodium falciparum - pathogenicity Plasmodium falciparum - physiology Polymerase chain reaction Product development Reagents RNA-directed DNA polymerase Safety Signs and symptoms Smear Sporozoites Studies Vaccines Vector-borne diseases |
| SummonAdditionalLinks | – databaseName: DOAJ (Directory of Open Access Journals) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQT1wQ5a8LBRmJAxzSJrHj2EdAVBUSCAkq9RaN_8RKu0nbJEjL6_AAPAQvxthxVl1UqRduUfwTxzNjfxNPviHklQePIJWjkyMKyDjumJmShc-YqEtvbc2qmD_l02dxesY_nlfn11J9hZiwiR54mrhjZZ3JbelZriQHwP3UcG60R02y2ru4-uYqn52paQ1GKxYi_SjH6uI4yeXoomvdUTgMEhXf2YgiX3_gN111_U1Y89-QyWt70Ml9ci-BR_p2GvQ-uePaB2Q_mWdPXycO6TcPya-v4N2wodBaOoWZT3zcG9p5msLTV87SmKKPfkEIve7sclxTD6sQZX2Fl3OcVkv1hq67_nJE66caMSoW0TWgT7yErIU_v3842o86fNHpKQwUKGJ17MlMT0RYTIPz3P3sQlszp295RM5OPnx7f5qlfAyZqUoxZAGbgXDM16A8LhXKlhy0LUvngTmNQAv9SwlQCCmVZIVWtWEGIaVWmmsL7DHZa1ECB4Q6bqyrK4vLh0apGsksQtNSgTBOaqcWhM3CaUwiKw85M1ZNPIGr0WmZprwJIm2SSBck27a6mMg6bqn_Lsh9WzdQbccbqIBNUsDmNgVckIOgNfMD-qZAl1Ki3yyx_8NZk24ufrktRqMOJzXQum6MdWrEcoyJBXkyKd52kGXE2CW2rndUcuctdkva5fdIHI7QWeRcPP0fr_2M3EXsyMNvmYU8JHvD1eieIz4b9Itoin8BKQhBhA priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3NjtMwELaW7oULYvnbwIKMxAEO2W1ix0kOCNFqqwWp1QpYaW_R-A8qdZNuf5DK6_AAPAQvxthxCkUruFW1rTiZmc_f2OMZQl5YsEhSOTo5IoGY44oZl0ViYyby1Gqds8zXTxlPxNkFf3-ZXe6RSXcXxoVVdpjogVo3yu2RnyRI1Av0Rgr-Zn4du6pR7nS1K6EBobSCfu1TjN0i-wjJWb9H9genk_MPHTajdQsRLtCxPDkJ8jqeN7U5dodEIuM7C5TP4-_yns6a5U0c9O9Qyj_WptFdcieQSvq21YIDsmfqe-QgmO2Svgy5pV_dJ98_gjWrDYVa02Gb-NtHx25oY-mwDVufGU393j49R2p91ejp-opamLno6wX-fBfit2oqN3TcLK_XiAp0gN-JTms6BvSVpxBP4OePr4YiMLmdniWFFQWKkEpHoNonIl2mrsh6861xY4ddWZcH5GJ0-ml4Foc6DbHKUrGKHWcDYZjNobQIIaVOOUidpsYCMxIJGPqdBUAiiqIsWCLLXDGFVFOWkksN7CHp1SiBQ0INV9rkmUZYkRxAFUwjZU1LEMoU0pQRYZ1wKhWSmLtaGrPKn8zl6My0n7xyIq2CSCMSb0fN2yQe_-k_cHLf9nUpuP0fzeJzFSy6KrVRfZ1a1i8LnCoSPcW5khYhTktr0ogcOq3pHrCsfmtwRI46Tbq5-fm2GY3dneBAbZq175Mjx2NMRORRq3jbSaaee6c4Ot9RyZ232G2pp198QnGk1KLPxeN_T-sJuY1skbuLmElxRHqrxdo8RUa2ks-Cmf0Cdgg8ww priority: 102 providerName: ProQuest |
| Title | Safety and Comparability of Controlled Human Plasmodium falciparum Infection by Mosquito Bite in Malaria-Naïve Subjects at a New Facility for Sporozoite Challenge |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/25405724 https://www.proquest.com/docview/1625884084 https://www.proquest.com/docview/1627075336 https://pubmed.ncbi.nlm.nih.gov/PMC4236046 https://doaj.org/article/9dec0d2f30984aa399c44cbf017dbfe2 http://dx.doi.org/10.1371/journal.pone.0109654 |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwELb2ceGCWF5bWCojcYBDqsZ2beeAELvaskJitQIq9Rb5CZXaZLdJEeXv8AP4Efwxxk5SUVQElyiKX4lnxv7GM5lB6JlXHkAqAyWHpyphsGMmmUx9Qrkg3lpBRzF_yrtLfjFhb6ej6R7qcra2E1jtVO1CPqnJcj74erN-BQL_MmZtEGnXaHBdFm4QTD18xPbRYbQYBWc-trErgHRH62VALQknQ9r-TPe3XrY2qxjTP8RAnZfVLjz6p1vlb_vU-A663QJM_LrhiCO054q76KgV4Qo_b-NMv7iHvn9Q3tVrrAqLG1f0Jmb3Gpcety7sc2dxTOOHrwBmL0o7Wy2wV_Pgib2E286Xq8B6jRdldbOCFQJrwLFQhBcKJnemkkL9_PHF4Wqlw6lPhVWNFQY8Dz2ZZkSAzjhQofxWhramS_FyH03G5x_PLpI2Z0NiRoTXScBvijvqhco8LCeZJUxpS4jzijoNYAx0UKlUyqXMJE11Jgw1ADt1ppm2ij5ABwVQ4Bhhx4x1YmRhidFMKSOpBfhKMsWNk9plPUQ74uSmDWge8mrM82ilE6DYNFOeB5LmLUl7KNm0um4Cevyj_mmg-6ZuCMcdH5TLT3kr3XlmnRla4ukwk_CqAPoMY0Z7WO6s9o700HHgmm6AKk9B7ZSgW0vo_6TjpN3FTzfFIPjBmqMKV65iHQF4j1LeQw8bxtu8JIk4nEBrscWSW1-xXVLMPsfg4gCv-ZDxR_8x7mN0C-AjC39mpvIEHdTLlXsCEK3WfbQvpgKu8iwN1_GbPjo8Pb-8et-Phx79KJW_AEnpRqU |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbhMxELZKeoALovw1UMBIIMFh26zteHcPFSKhUUKbqIJW6m3xL0RKd9NsAgqvwwPwBlx4Mca73kBQBafeotjOejPjz994xjMIPbPCAkllYOTwUAQMdswgiUMbUB4Rq3VE22X9lOGI90_Z27P22Qb6Ud-FcWGVNSaWQK1z5c7I90Ig6jFYIzF7Nb0IXNUo512tS2gIX1pB75cpxvzFjkOz_AImXLE_eAPyfk5I7-Ck2w98lYFAtQmfB45xCG6ojURiYQEkmjAhNSHGCmok0AewmmIhQh7HSUxDmUSKKiBKMpFMakHhd6-hTeYOUBpos3MwOn5X7wWAJpz7C3s0Cve8fuxO88zsOqcUb7O1DbGsG-DyrE7y4jLO-3fo5h97Ye8WuulJLH5dad0W2jDZbbTlYaLAL3wu65d30Lf3wpr5EotM426VaLyMxl3i3OJuFSY_MRqXvgR8DFT-PNfjxTm2YuKivWfwceDjxTIsl3iYFxcLQCHcAbngcYaHAmzzsQhG4uf3zwYDELqTpQKLORYYIBz3hKqeCPQcu6Lu-dfcje3WZWTuotMrkdg91MhAAtsIG6a0idoaYEwyIVRMNVBkkgiuTCxN0kS0Fk6qfNJ0V7tjkpaewAiMp-ovT51IUy_SJgpWo6ZV0pD_9O84ua_6upTf5Rf57GPqESRNtFEtTSxtJTFMFYilYkxJC5CqpTWkibad1tQPKNLfK6aJdmpNurz56aoZwMV5jERm8kXZJwJOSSlvovuV4q0mSUquT2B0tKaSa2-x3pKNP5UJzIHC8xbjD_49rSfoev9keJQeDUaHD9ENYKrMXQIN4x3UmM8W5hGwwbl87JccRh-uepX_AlfFeWI |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dbtMwFLbGJiFuEONvhQFGAgkusja26yQXE6LdqpXRqgIm7S7zL1Tqkq5pQeV1eAAegjueiuPEKRRNcLW7KrYbJ-f483dyjs9B6JkVFkgqAyOHhyJgsGMGSRzagPKIWK0j2i7rpwyG_OiEvTltn26gn_VZGBdWWWNiCdQ6V-4beTMEoh6DNRKzpvVhEaOD3qvpReAqSDlPa11OQ_gyC3q_TDfmD3kcm-UXMOeK_f4ByP45Ib3DD92jwFccCFSb8Hng2IfghtpIJBYWQ6IJE1ITYqygRgKVAAsqFiLkcZzENJRJpKgC0iQTyaQWFP73GtqKYNcHQ3Crczgcvav3BUAWzv3hPRqFTa8re9M8M3vOQcXbbG1zLGsIuJyrk7y4jP_-Hcb5x77Yu4VuekKLX1cauI02THYbbXvIKPALn9f65R307b2wZr7EItO4WyUdLyNzlzi3uFuFzE-MxqVfAY-A1p_nerw4x1ZMXOT3DH72fexYhuUSD_LiYgGIhDsgFzzO8ECAnT4WwVD8-P7ZYABF95WpwGKOBQY4xz2hqjsCVceuwHv-NXdju3VJmbvo5Eokdg9tZiCBHYQNU9pEbQ2QJpkQKqYa6DJJBFcmliZpIFoLJ1U-gbqr4zFJS69gBIZU9cpTJ9LUi7SBgtWoaZVA5D_9O07uq74u_Xd5IZ99TD2apIk2qqWJpa0khqmCuinGlLQAr1paQxpox2lNfYMi_b16Gmi31qTLm5-umgFonPdIZCZflH0i4JeU8ga6XyneapKk5P0ERkdrKrn2FOst2fhTmcwc6DxvMf7g39N6gq7Dak_f9ofHD9ENIK3MnQcN4120OZ8tzCMghnP52K84jM6uepH_AtawfaY |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+comparability+of+controlled+human+Plasmodium+falciparum+infection+by+mosquito+bite+in+malaria-na%C3%AFve+subjects+at+a+new+facility+for+sporozoite+challenge&rft.jtitle=PloS+one&rft.au=Talley%2C+Angela+K&rft.au=Healy%2C+Sara+A&rft.au=Finney%2C+Olivia+C&rft.au=Murphy%2C+Sean+C&rft.date=2014-11-18&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=9&rft.issue=11&rft.spage=e109654&rft_id=info:doi/10.1371%2Fjournal.pone.0109654&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |